690 M.A. Huestis
Soares JR, Gross SJ (1976) Separate radioimmune measurements of body fluid delta-9THC
and 11-nor-9-carboxy-delta-THC. Life Sci 19:1711–1717
Soares JR, Grant JD, Gross SJ (1982) Significant developments in radioimmune methods ap-
plied to delta-9-THC and its 9-substituted metabolites. In: Hawks R (ed) NIDA Research
Monograph 42: National Institute on Drug Abuse, Bethesda, pp 44–55
Sporkert F, Pragst F, Ploner CJ, Tschirch A, Stadelmann AM (2001) Pharmacokinetic inves-
tigations and delta-9-tetrahydrocannabinol and its metabolites after single administra-
tion of 10 mg Marinol in attendance of a psychiatric study. The Annual Meeting of The
International Association of Forensic Toxicologists, Prague, pp 1–62
Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR (2004) Human skin permeation of
delta-8-tetrahydrocannabinol, cannabidiol and cannabinol. J Pharm Pharmacol 56:291–
297
Turner CE, ElSohly MA, Boeren EG (1980) Constituents of cannabis sativa L. XVII. A review
of the natural constituents. J Nat Prod 43:169–234
Vaughan CW, Christie MJ (1984) Mechanisms of cannabinoid analgesia. In: Grotenhermen
F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic
potential. The Haworth Integrative Healing Press, New York, pp 89–100
WallME,Perez-ReyesM(1981)Themetabolismofdelta-9-tetrahydrocannabinolandrelated
cannabinoids in man. J Clin Pharmacol 21:178S–189S
Wall ME, Taylor HL (1984) Conjugation of acidic metabolites of delta-8 and delta-9-THC in
man. In: Harvey DJ, Paton SW, Nahas GG (eds) Marihuana 84 Proceedings of the Oxford
Symposium on Cannabis. IRL Press Limited, Oxford, pp 69–76
Wall ME, Brine DR, Perez-Reyes M (1976) Metabolism of cannabinoids in man. In: Braude
MC, Szara S (eds) The Pharmacology of marihuana. Raven Press, New York, pp 93–113
Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M (1983) Metabolism, disposition,
and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther
34:352–363
Watanabe K, Tanaka T, Yamamoto I, Yoshimura H (1988) Brain microsomal oxidation of
delta-8- and delta-9-tetrahydrocannabinol. Biochem Biophys Res Commun 157:75–80
Widman M, Agurell S, Ehrnebo M, Jones G (1974) Binding of (+) and (–)-delta1-tetrahydro-
cannabinols and (–)-7-hydroxy-delta1-tetrahydrocannabinol to blood cells and plasma
proteins in man. J Pharm Pharmacol 26:914–916
Widman M, Nordqvist M, Dollery CT, Briant RH (1975) Metabolism of delta-1-tetra-
hydrocannabinol by the isolated perfused dog lung. Comparison with in vitro liver
metabolism. J Pharm Pharmacol 27:842–848
Williams PL, Moffat AC (1980) Identification in human urine of delta-9-tetrahydrocannabi-
nol-11-oic glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 32:445–
448
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids
for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS
study): multicentre randomised placebo-controlled trial. Lancet 362:1517–1526
Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety
and other effects produced by delta-9-THC in normal subjects. Psychopharmacology
(Berl) 76:245–250